Growth Hormone Peptides: CJC-1295, Ipamorelin, MK-677

Growth hormone secretagogues sit at the center of nearly every bodybuilding peptide protocol. Rather than injecting exogenous GH directly, these compounds stimulate the pituitary gland to release its own growth hormone in pulsatile patterns that more closely mimic natural physiology. Three compounds dominate this category: CJC-1295, Ipamorelin, and MK-677. Each works through a different mechanism, carries a different side-effect profile, and serves a different role in a well-designed stack. This guide breaks down all three in detail.

How Endogenous GH Release Actually Works

Before diving into individual compounds, understanding the hypothalamic-pituitary GH axis is essential. Growth hormone release is governed by two opposing signals from the hypothalamus: growth hormone-releasing hormone (GHRH), which stimulates GH secretion, and somatostatin, which inhibits it. These two signals create the pulsatile pattern of GH release seen in healthy adults, with the largest pulse occurring roughly 60 to 90 minutes after falling asleep.

GH secretagogues work by amplifying one or both sides of this equation. GHRH analogs like CJC-1295 increase the amplitude of GH pulses by mimicking the "release" signal. Ghrelin mimetics like Ipamorelin and MK-677 activate the growth hormone secretagogue receptor (GHS-R), which both stimulates GH release and partially suppresses somatostatin. When you combine both pathways, you get a synergistic effect that exceeds what either mechanism achieves alone. This synergy is the foundation of the CJC-1295/Ipamorelin stack that has become standard practice in the bodybuilding peptide community.

CJC-1295: The GHRH Analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone with 29 amino acids, modified to resist enzymatic degradation. It exists in two forms that are frequently confused: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, which is more accurately called Modified GRF (1-29) or sometimes sold as "Mod GRF." The distinction between these two forms has significant practical implications for dosing and use.

CJC-1295 with DAC

The DAC modification allows CJC-1295 to bind to albumin in the bloodstream, extending its half-life from roughly 30 minutes to approximately 8 days. This creates a sustained elevation of baseline GH levels rather than distinct pulses. In clinical studies, a single 30 mcg/kg injection of CJC-1295 DAC elevated mean GH concentrations by 2 to 10-fold for 6 days or longer, with IGF-1 levels remaining elevated for up to 14 days.

The extended half-life makes dosing convenient, typically once or twice per week at 1000 to 2000 mcg per injection. However, the sustained GH elevation blunts the natural pulsatile release pattern. Some researchers in the bodybuilding space argue this continuous exposure leads to faster desensitization of GH receptors and more pronounced side effects like water retention and joint discomfort. The DAC version also produces a more consistent elevation of cortisol and prolactin as secondary effects.

CJC-1295 without DAC (Mod GRF 1-29)

Without the DAC modification, this peptide retains the GH-releasing activity of GHRH but with a half-life of roughly 30 minutes. This shorter duration means it creates distinct, sharp GH pulses rather than a sustained elevation. Each injection produces a GH spike that peaks within 15 to 30 minutes and returns to baseline within 2 to 3 hours, closely mimicking the body's own pulsatile rhythm.

Standard dosing is 100 mcg per injection, administered 2 to 3 times daily. The most common protocol involves a pre-bed injection (to amplify the natural nocturnal GH surge), a post-workout injection, and optionally a fasted morning injection. Because the GH elevation is transient, receptor desensitization is less of a concern, and side effects tend to be milder. For bodybuilding applications, the no-DAC version is generally preferred, particularly when stacking with Ipamorelin.

Ipamorelin: The Selective GHRP

Ipamorelin is a pentapeptide that acts as a selective growth hormone releasing peptide (GHRP) by agonizing the ghrelin receptor (GHS-R1a). What sets Ipamorelin apart from earlier ghrelin mimetics like GHRP-6 and GHRP-2 is its selectivity. In research models, Ipamorelin stimulates GH release with minimal impact on cortisol, prolactin, and ACTH levels, even at doses 100 times the effective GH-releasing dose. This selectivity is its primary advantage.

Mechanism and Pharmacology

Ipamorelin binds to GHS-R1a on pituitary somatotrophs, triggering a calcium-dependent signaling cascade that leads to GH vesicle exocytosis. Unlike GHRP-6, which produces a strong appetite-stimulating effect through peripheral ghrelin receptor activation, Ipamorelin's appetite effects are considerably muted. It also does not significantly elevate aldosterone or cortisol, making it a cleaner GH secretagogue for body composition purposes where managing water retention and stress hormones matters.

The half-life of Ipamorelin is approximately 2 hours, with peak GH release occurring 30 to 40 minutes after subcutaneous administration. GH levels return to baseline within 3 hours. In dose-escalation studies, the GH response plateaus at roughly 200 to 300 mcg per injection, with no additional benefit from higher doses.

Dosing Protocols

Standard Ipamorelin dosing is 100 to 300 mcg per injection, 2 to 3 times daily. The most widely used approach is 200 mcg per injection. Key timing considerations include:

• Pre-bed (primary dose): 200-300 mcg administered 30 to 60 minutes before sleep. This amplifies the natural nocturnal GH pulse, which is already the largest of the day.
• Post-workout: 100-200 mcg within 30 minutes of training. Capitalizes on the exercise-induced GH secretion window.
• Fasted morning: 100-200 mcg on waking, at least 30 minutes before eating. Blood glucose and insulin should be low, as insulin blunts the GH response.

MK-677 (Ibutamoren): The Oral Ghrelin Mimetic

MK-677, also known as Ibutamoren, is a non-peptide, orally active growth hormone secretagogue. Unlike CJC-1295 and Ipamorelin, MK-677 is not a peptide at all. It is a small molecule that mimics the action of ghrelin at the GHS-R1a receptor. Its oral bioavailability and long half-life (approximately 24 hours) make it uniquely convenient among GH secretagogues, requiring only a single daily dose.

Mechanism and Clinical Data

MK-677 activates the same ghrelin receptor as Ipamorelin but does so as a non-selective agonist. This means it not only stimulates GH release but also significantly increases appetite, mimicking the physiological effects of ghrelin more broadly. In clinical trials, 25 mg daily of MK-677 increased 24-hour GH secretion by approximately 97% in young healthy subjects and elevated IGF-1 levels by 40 to 60% within 2 weeks, with levels remaining elevated for the duration of treatment.

One of the most cited studies examined MK-677 in healthy older adults over 2 years. Daily dosing of 25 mg restored IGF-1 and GH secretory profiles to those of healthy young adults. Fat-free mass increased significantly in the first year. However, the study also documented consistent increases in fasting blood glucose and insulin resistance markers, which became more pronounced over time.

Body Composition Research

Multiple trials support MK-677's effects on body composition. In diet-restricted subjects, 25 mg daily reversed nitrogen wasting and preserved lean body mass, suggesting anti-catabolic properties during caloric deficits. In a separate study of obese subjects, 2 months of MK-677 increased GH secretion and trended toward increased fat-free mass, though results were not uniformly significant across all body composition endpoints.

The bodybuilding community primarily values MK-677 for three effects: elevated IGF-1 (which supports muscle protein synthesis and recovery), improved sleep quality (multiple studies document increased Stage 4 deep sleep duration by up to 50%), and enhanced appetite for those in a gaining phase. The appetite stimulation, however, makes MK-677 a poor choice during cutting phases for most individuals.

Dosing and Administration

Standard dosing is 10 to 25 mg daily, taken orally. Most research uses 25 mg, though some bodybuilding protocols start at 10 to 15 mg to assess tolerance before escalating. Because MK-677 has a 24-hour half-life, timing is less critical than with injectable secretagogues. However, many users prefer a pre-bed dose to leverage the sleep-quality benefits and to minimize the impact of appetite stimulation during waking hours. Some split the dose (12.5 mg morning, 12.5 mg evening) to reduce peak-related side effects.

Sleep-Dose Protocols

The pre-bed dosing strategy deserves special attention because it is where GH secretagogues deliver their most pronounced effects. The largest natural GH pulse occurs during slow-wave (Stage 3/4) sleep, typically within the first 90 minutes of falling asleep. Administering a secretagogue 30 to 60 minutes before bed amplifies this pulse dramatically.

Clinical data on MK-677 shows a 50% increase in Stage 4 sleep duration and a 20% increase in REM sleep duration compared to placebo. When combined with the GH-amplifying effect, the pre-bed window becomes the single most productive dose of the day for body composition purposes. Recovery, tissue repair, and fat oxidation are all enhanced during deep sleep, and a higher-amplitude GH pulse during this window compounds these effects.

For injectable protocols, the standard pre-bed approach is to administer CJC-1295 (no DAC) at 100 mcg and Ipamorelin at 200 to 300 mcg simultaneously, 30 to 60 minutes before sleep on an empty stomach. For MK-677, 25 mg taken 30 minutes before bed is the typical protocol. Some advanced users combine all three: the injectable CJC/Ipamorelin stack plus oral MK-677, though this carries a higher side-effect burden and questionable additional benefit given the overlapping mechanisms at the ghrelin receptor.

Stacking CJC-1295, Ipamorelin, and MK-677

The rationale for stacking GH secretagogues comes down to pathway synergy. CJC-1295 (no DAC) works through the GHRH receptor, while Ipamorelin works through the ghrelin receptor. These are two distinct pathways that converge on the same outcome: pituitary GH release. When activated simultaneously, the resulting GH pulse is significantly larger than either compound alone. Research on GHRH + GHRP co-administration consistently shows a synergistic rather than merely additive effect, with combined GH output exceeding the sum of individual responses.

The Standard CJC/Ipamorelin Stack

This is the most widely used bodybuilding GH secretagogue protocol. A typical approach:

• CJC-1295 no DAC: 100 mcg per injection
• Ipamorelin: 200 mcg per injection
• Frequency: 2-3 times daily (pre-bed mandatory, post-workout recommended, fasted morning optional)
• Duration: 8-16 week cycles, with some running continuously at lower frequency

The two peptides are often reconstituted separately but drawn into the same syringe for a single subcutaneous injection. Timing rules remain the same: empty stomach, at least 2 hours after eating, no food for 30 minutes after injection to avoid insulin-mediated blunting of the GH response.

Adding MK-677 to the Stack

MK-677 can be layered on top of the CJC/Ipamorelin stack, but the overlap at the ghrelin receptor means the incremental benefit is debatable. MK-677 and Ipamorelin both act on GHS-R1a, so running them concurrently creates redundancy rather than synergy at that receptor. The primary rationale for including MK-677 alongside Ipamorelin is its sustained 24-hour IGF-1 elevation, sleep benefits, and convenience as an oral compound that maintains baseline GH support between injections.

A practical approach used by some researchers involves running CJC/Ipamorelin injections 2 to 3 times daily alongside a lower dose of MK-677 (10 to 15 mg rather than the full 25 mg) to capture the IGF-1 and sleep benefits without excessive ghrelin receptor saturation. Others alternate: using CJC/Ipamorelin during an active training cycle and switching to MK-677 alone during deload or travel periods when injection convenience matters.

GH Pulse Data: What the Numbers Show

Understanding the magnitude of GH pulses produced by each compound helps contextualize their relative potency and practical value for body composition outcomes.

The combined CJC/Ipamorelin stack produces peak GH levels that approach those of low-dose exogenous GH, but in a pulsatile pattern with full negative feedback intact. The body retains its ability to regulate GH production, which is a key advantage over exogenous GH administration where the pituitary is suppressed. MK-677 achieves comparable or higher IGF-1 elevation through sustained rather than pulsatile GH release, which is a meaningfully different physiological stimulus.

Side Effects: Compound by Compound

CJC-1295 (Both Forms)

• Flushing and warmth: Transient facial flushing within minutes of injection is the most common side effect. Typically lasts 5 to 15 minutes and diminishes with continued use.
• Water retention: Mild to moderate, more pronounced with the DAC version due to sustained GH elevation.
• Tingling/numbness: Carpal tunnel-like symptoms in the hands and fingers, typically at higher doses or with DAC. Indicates elevated GH activity.
• Injection-site reactions: Redness or minor irritation at the injection site, generally mild.

Ipamorelin

• Head rush or lightheadedness: Occasional, typically only with the first few doses or at higher amounts (300+ mcg).
• Mild appetite increase: Present but significantly less than GHRP-6 or MK-677. Does not typically disrupt cutting protocols.
• Minimal cortisol/prolactin impact: This is Ipamorelin's distinguishing feature. Cortisol and prolactin remain near baseline even at supraphysiological doses, unlike GHRP-2 and GHRP-6 which elevate both.
• Transient nausea: Rare, usually associated with administration on an overly empty stomach or dehydration.

MK-677

• Appetite stimulation: The most prominent side effect. Often intense in the first 2 to 4 weeks before partially attenuating. Can add 500 or more unwanted calories per day if not managed.
• Water retention and bloating: More pronounced than either injectable secretagogue. Typically peaks in weeks 2 to 4 and stabilizes. Related to aldosterone-like activity.
• Elevated fasting glucose and insulin resistance: Clinically documented with chronic use. Fasting glucose may rise 5 to 15 mg/dL. This effect persists for the duration of use and warrants monitoring, particularly in individuals with pre-existing metabolic concerns.
• Lethargy and vivid dreams: Commonly reported with pre-bed dosing. The lethargy is partly attributable to the increased deep sleep duration. Vivid dreams or lucid dreaming occur frequently.
• Joint pain and numbness: Carpal tunnel-like symptoms similar to CJC-1295, indicating elevated GH/IGF-1 activity.

Head-to-Head Comparison

Practical Recommendations

Choosing between these three compounds depends on goals, tolerance for side effects, and lifestyle factors. For body recomposition or cutting phases, the CJC-1295 (no DAC) plus Ipamorelin injectable stack is generally the preferred approach. It produces meaningful GH pulses with minimal appetite stimulation, no insulin resistance concerns, and clean hormonal profiles. The trade-off is the need for 2 to 3 daily injections, which requires discipline and proper peptide storage.

For gaining phases where appetite stimulation is welcome, MK-677 at 25 mg daily offers a no-injection alternative with substantial IGF-1 elevation and documented sleep benefits. It is also the most practical option for those who travel frequently or prefer oral administration. The metabolic side effects (fasting glucose elevation, water retention) should be monitored with periodic bloodwork, and many experienced users limit continuous MK-677 use to 3 to 6 months before cycling off.

For those who want the best of both worlds, a combination stack using CJC/Ipamorelin injections alongside a reduced MK-677 dose (10 to 15 mg) captures the pulsatile GH benefits, the sustained IGF-1 elevation, and the sleep improvements. This approach does carry the highest overall side-effect burden and cost, so it is typically reserved for experienced users who have already run each compound individually.

Regardless of which protocol is chosen, the foundational principles remain the same: administer on an empty stomach, prioritize the pre-bed dose, monitor fasting glucose and IGF-1 levels with bloodwork, and cycle usage to prevent receptor desensitization. These are powerful research compounds that interact with fundamental hormonal axes. Understanding their mechanisms, limitations, and interactions is what separates an informed approach from guesswork.